

CE-IVD approved Therascreen PIK3CA dx

written by CAP TODAY

March 19, 2020

March 2020—Qiagen announced the CE marking and launch of its Therascreen PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients with a *PIK3CA* mutation. The Therascreen PIK3CA test was approved in 2019 by the FDA and launched in the U.S. as a companion diagnostic test for Piqray (alpelisib).

The Therascreen assay detects 11 clinically actionable *PIK3CA* mutations and enables testing of DNA from formalin-fixed, paraffin-embedded tissue or plasma specimens.

[Qiagen](#), 800-426-8157



©2026 CAP TODAY, all rights reserved.